The latest price target for Edwards Lifesciences (NYSE:EW) was reported by Canaccord Genuity on October 25, 2024. The analyst firm set a price target for $63.00 expecting EW to fall to within 12 months (a possible -9.40% downside). 64 analyst firms have reported ratings in the last year.

The latest analyst rating for Edwards Lifesciences (NYSE:EW) was provided by Canaccord Genuity, and Edwards Lifesciences maintained their hold rating.

The last upgrade for Edwards Lifesciences Corp happened on July 29, 2024 when Wolfe Research raised their price target to N/A. Wolfe Research previously had an underperform for Edwards Lifesciences Corp.

The last downgrade for Edwards Lifesciences Corp happened on September 18, 2024 when Jefferies changed their price target from $85 to $70 for Edwards Lifesciences Corp.

Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of Edwards Lifesciences, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for Edwards Lifesciences was filed on October 25, 2024 so you should expect the next rating to be made available sometime around October 25, 2025.

While ratings are subjective and will change, the latest Edwards Lifesciences (EW) rating was a maintained with a price target of $66.00 to $63.00. The current price Edwards Lifesciences (EW) is trading at is $69.54, which is out of the analyst’s predicted range.